Prot# S1103: A Phase I, Open-Label, Non-Randomized, Dose-Finding, Safety, Tolerance, and Pharmacokinetic Study of Orally Administered S-1 in Combination with Gemcitabine and Erlotinib in Patients with Advanced Solid Tumors